Table 3.

Summary of Treatment-Emergent AEs

AE	Abagovomab		Placebo
	No.	%	No.	%
Treatment-emergent AE	564	95.3	278	94.6
Grade 3 AE	115	19.4	67	22.8
Grade 4 AE	12	2.0	5	1.7
Treatment-emergent related AE	507	85.6	246	83.7
SAE	141	23.8	72	24.5
Treatment-related SAE	12	2.0	3	1.0
SAE leading to withdrawal of study drug	93	15.7	57	19.4

Abbreviations: AE, adverse event; SAE, serious adverse event.